Yanan Zhu: Got it. Very helpful. Thank you.
Operator: Our next question comes from Peter Lawson of Barclays. Please go ahead.
Peter Lawson: Great. Thanks for taking the question. Just going back to the cash guidance. Just curious if that includes commercial products from both Adaptimmune and TCR2?
Adrian Rawcliffe: So the only product that would be launching within that timeframe would be afami-cel for the treatment of synovial sarcoma. It doesn’t include revenue from those products, no. So from that product, no is the simple answer to that. That would be additive to that. And we’ve said that we will comment more on our commercial plans as we get through registration. So it’s inherently a conservative approach to what we might do with afami-cel.
Peter Lawson: Perfect. And then I guess a question for Garry, whether this was a competitive process, how long did this take? And is there any breakup fees for this?
Garry Menzel: So last question first. Yes, there are breakup fees, standard breakup fees. I would say, first of all, that there will be an S-4 coming out that will provide full details of the dialogue. What I can tell you now, because you’ll have to wait until then for that is Ad and I have known each other for a couple of decades. So even before we were both specialized in cell therapy, we had an ongoing dialogue and, of course, with preeminent cell therapy for a number of years now, not surprisingly being at the forefront of our deals, we’ve had ongoing dialogue just in terms of our thoughts in the field. But in terms of this particular process, the fall of last year was when we began to have discussions in earnest and you’ll see more of that. In other words, this was a thoughtful process, and we’re always talking to a lot of people in the field. So, that’s all I think we can say at this point.
Peter Lawson: Got you. Can you disclose the breakup fees? Or do we have to wait for the filings?
Garry Menzel: You’ll have to wait for the filings.
Peter Lawson: Okay. And then just going back to the cash runway guidance. Does that include potentially further rationalization of the combined pipeline? Is that something you foresee doing? Is that something we have to wait until 2Q? Or is it kind of a data-driven thing? Or should you just look at that pipeline as the go forward?
Adrian Rawcliffe: So, I think all of the above. Yes, it’s a data-driven thing. The pipeline that we’ve put out there is the pro forma combined pipeline of the companies, and we will make data-driven. And based on the catalysts that we’ve outlined to you, those will be the data points when we’ll be able to make decisions about development pathways for those assets.
Operator: This concludes the question-and-answer session. I will now turn the call back over to Adrian Rawcliffe for any closing remarks.
Adrian Rawcliffe: So, I’d just like to close by referring you back to the five rationales for why this is a compelling transaction at this point in time; the solid tumor focus, the catalysts achievable within the extended runway, the deep innovative pipeline and the end-to-end capabilities that both companies have shown that I think between them in the combination will make this a compelling cell therapy company for the future. Thank you very much, and look forward to catch up conversations with many of you in due course.
Operator: This concludes today’s conference call. You may disconnect your lines. Thank you for participating, and have a pleasant day.+
